Group 1 - The core viewpoint of the articles highlights a strong performance in the Hong Kong pharmaceutical and biotechnology sector, with the Hang Seng Healthcare Index rising by 1.69% and reaching over 2.2% at one point [1] - The Hang Seng Medical Index ETF (159557) saw an increase of 1.34% with a trading volume exceeding 11 million, indicating active trading [1] - Notable stock performances include Green Leaf Pharmaceutical rising over 10%, and several other companies like Haijia Medical and Kangzhe Pharmaceutical increasing by over 8% [1] Group 2 - The issuance of 225 million shares by Hengrui Medicine in Hong Kong led to a stock price increase of over 33% during trading [1] - The current market environment suggests a focus on innovative drugs in Hong Kong, driven by the potential for excess returns as companies establish global competitive advantages [2] - The global competitive advantage of Chinese innovative drugs is becoming more apparent, with significant growth in License-out transactions in overseas markets [2] Group 3 - Recent policy and regulatory changes are favorable for the sector, including optimization of centralized procurement rules and increased support for innovative drugs [2] - Financially, leading Hong Kong innovative pharmaceutical companies are benefiting from increased License-out volumes, resulting in steady revenue and profit growth [2] - The valuation of the pharmaceutical sector remains relatively safe compared to other growth industries, indicating a favorable investment environment [2]
恒生医疗指数ETF（159557） 涨逾1%，绿叶制药涨超10%，机构：当前时刻建议重视港股创新药